BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 23845472)

  • 1. The β5/focal adhesion kinase/glycogen synthase kinase 3β integrin pathway in high-grade osteosarcoma: a protein expression profile predictive of response to neoadjuvant chemotherapy.
    Le Guellec S; Moyal EC; Filleron T; Delisle MB; Chevreau C; Rubie H; Castex MP; de Gauzy JS; Bonnevialle P; Gomez-Brouchet A
    Hum Pathol; 2013 Oct; 44(10):2149-58. PubMed ID: 23845472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of tumor suppressors in osteosarcoma before and after neoadjuvant chemotherapy.
    Robl B; Pauli C; Botter SM; Bode-Lesniewska B; Fuchs B
    BMC Cancer; 2015 May; 15():379. PubMed ID: 25956431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. pFAK-Y397 overexpression as both a prognostic and a predictive biomarker for patients with metastatic osteosarcoma.
    Thanapprapasr K; Nartthanarung A; Thanapprapasr D; Jinawath A
    PLoS One; 2017; 12(8):e0182989. PubMed ID: 28846700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. P16 expression predicts necrotic response among patients with osteosarcoma receiving neoadjuvant chemotherapy.
    Borys D; Canter RJ; Hoch B; Martinez SR; Tamurian RM; Murphy B; Bishop JW; Horvai A
    Hum Pathol; 2012 Nov; 43(11):1948-54. PubMed ID: 22578565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p16 expression predicts neoadjuvant tumor necrosis in osteosarcomas: reappraisal with a larger series using whole sections.
    Kosemehmetoglu K; Ardic F; Karslioglu Y; Kandemir O; Ozcan A
    Hum Pathol; 2016 Apr; 50():170-5. PubMed ID: 26997452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated Expression of Transforming Acidic Coiled-Coil Containing Protein 3 (TACC3) Is Associated With a Poor Prognosis in Osteosarcoma.
    Matsuda K; Miyoshi H; Hiraoka K; Hamada T; Nakashima K; Shiba N; Ohshima K
    Clin Orthop Relat Res; 2018 Sep; 476(9):1848-1855. PubMed ID: 30024460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant Chemotherapy Followed by Delayed Surgery: Is it Necessary for All Patients With Nonmetastatic High-Grade Pelvic Osteosarcoma?
    Xu J; Xie L; Guo W
    Clin Orthop Relat Res; 2018 Nov; 476(11):2177-2186. PubMed ID: 29912746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycogen synthase kinase 3β promotes osteosarcoma invasion and migration via regulating PTEN and phosphorylation of focal adhesion kinase.
    Mai W; Kong L; Yu H; Bao J; Song C; Qu G
    Biosci Rep; 2021 Jul; 41(7):. PubMed ID: 33969873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p16 expression as a prognostic and predictive marker in high-grade localized osteosarcoma of the extremities: an analysis of 357 cases.
    Righi A; Gambarotti M; Sbaraglia M; Sisto A; Ferrari S; Dei Tos AP; Picci P
    Hum Pathol; 2016 Dec; 58():15-23. PubMed ID: 27544803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Focal adhesion kinase overexpression and its impact on human osteosarcoma.
    Ren K; Lu X; Yao N; Chen Y; Yang A; Chen H; Zhang J; Wu S; Shi X; Wang C; Sun X
    Oncotarget; 2015 Oct; 6(31):31085-103. PubMed ID: 26393679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significance of neoadjuvant chemotherapy (NACT) in limb salvage treatment of osteosarcoma and its effect on GLS1 expression.
    Zhang SP; Li X; Li H; Sun XH; Yan XF
    Eur Rev Med Pharmacol Sci; 2018 Oct; 22(19):6538-6544. PubMed ID: 30338824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vitronectin significantly influences prognosis in osteosarcoma.
    Shi K; Lan RL; Tao X; Wu CY; Hong HF; Lin JH
    Int J Clin Exp Pathol; 2015; 8(9):11364-71. PubMed ID: 26617861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of immunohistochemical expression of ezrin in non-metastatic high-grade osteosarcoma.
    Ferrari S; Zanella L; Alberghini M; Palmerini E; Staals E; Bacchini P
    Pediatr Blood Cancer; 2008 Apr; 50(4):752-6. PubMed ID: 17886294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of 18F-FDG PET/CT and diffusion-weighted MR imaging as a predictor of histologic response to neoadjuvant chemotherapy: preliminary results in osteosarcoma.
    Byun BH; Kong CB; Lim I; Choi CW; Song WS; Cho WH; Jeon DG; Koh JS; Lee SY; Lim SM
    J Nucl Med; 2013 Jul; 54(7):1053-9. PubMed ID: 23670899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of HLA-DR expression and T-lymphocyte infiltration in osteosarcoma.
    Trieb K; Lechleitner T; Lang S; Windhager R; Kotz R; Dirnhofer S
    Pathol Res Pract; 1998; 194(10):679-84. PubMed ID: 9820863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Expression analysis of protein tyrosine kinases of the FAK (focal adhesion kinase) family in osteosarcoma].
    Schröder A; Delling G; Kaiser EA
    Pathologe; 2002 Sep; 23(5):361-6. PubMed ID: 12376862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment algorithm for locally recurrent osteosarcoma based on local disease-free interval and the presence of lung metastasis.
    Nathan SS; Gorlick R; Bukata S; Chou A; Morris CD; Boland PJ; Huvos AG; Meyers PA; Healey JH
    Cancer; 2006 Oct; 107(7):1607-16. PubMed ID: 16933325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ROCK1 as a potential therapeutic target in osteosarcoma.
    Liu X; Choy E; Hornicek FJ; Yang S; Yang C; Harmon D; Mankin H; Duan Z
    J Orthop Res; 2011 Aug; 29(8):1259-66. PubMed ID: 21387396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols.
    Kager L; Zoubek A; Pötschger U; Kastner U; Flege S; Kempf-Bielack B; Branscheid D; Kotz R; Salzer-Kuntschik M; Winkelmann W; Jundt G; Kabisch H; Reichardt P; Jürgens H; Gadner H; Bielack SS;
    J Clin Oncol; 2003 May; 21(10):2011-8. PubMed ID: 12743156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular characterization of the response to chemotherapy in conventional osteosarcomas: predictive value of HSD17B10 and IFITM2.
    Salas S; Jézéquel P; Campion L; Deville JL; Chibon F; Bartoli C; Gentet JC; Charbonnel C; Gouraud W; Voutsinos-Porche B; Brouchet A; Duffaud F; Figarella-Branger D; Bouvier C
    Int J Cancer; 2009 Aug; 125(4):851-60. PubMed ID: 19449377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.